| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The parent compound Tasquinimod targets the regulatory Zn²⁺ binding domain of HDAC4 with a Kd of 10-30 nM, thereby influencing histone deacetylation processes. It also has anti-angiogenic activity and plays an important role in castration-resistant prostate cancer. Tasquinimod-d3 serves as a deuterated internal standard for LC-MS/MS bioanalysis, enabling accurate quantitation of the parent compound in pharmacokinetic studies.
|
|---|---|
| ln Vitro |
In vitro activity of Tasquinimod-d3 is related to its function as an internal standard for LC-MS/MS bioanalysis of Tasquinimod. Its +3 Da mass shift enables unambiguous chromatographic and mass spectrometric differentiation from the non-deuterated analyte. The parent compound, Tasquinimod, demonstrates 30- to 60-fold greater potency than the first-generation analog linomide in preclinical prostate cancer models. Tasquinimod binds to the HDAC4 Zn²⁺ regulatory domain with a Kd of 10-30 nM.
|
| ln Vivo |
In vivo activity of Tasquinimod-d3 is studied in the context of pharmacokinetic studies where it serves as an internal standard for quantitation of Tasquinimod. The parent compound Tasquinimod is an oral anti-angiogenic agent investigated for castration-resistant prostate cancer. It demonstrates anti-tumor activity in preclinical prostate cancer models. The deuterated isotopologue is validated for plasma, serum, and tissue homogenate quantification.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Tasquinimod-d3 is not applicable in the traditional sense, as the compound is an internal standard rather than an enzyme inhibitor or receptor ligand. However, binding studies for the parent compound Tasquinimod have been performed, showing binding to the HDAC4 Zn²⁺ regulatory domain with a Kd of 10-30 nM. Tasquinimod-d3 is used in LC-MS/MS bioanalytical method validation where it co-elutes with the unlabeled analyte while remaining independently detectable via MS.
|
| Cell Assay |
In vitro cell-based assays for Tasquinimod-d3 are not directly applicable, as the compound is primarily an analytical internal standard. However, the parent compound Tasquinimod has been studied in prostate cancer cell lines to evaluate its anti-angiogenic and anti-tumor activity. Tasquinimod-d3 may be used in cell-based assays as a tracer to study drug uptake and metabolism. Standard protocols include appropriate controls and analytical methods for quantitation.
|
| Animal Protocol |
In vivo animal studies for Tasquinimod-d3 are typically conducted in pharmacokinetic studies where the compound serves as an internal standard for quantitation of Tasquinimod in plasma, serum, and tissue homogenates. The parent compound has been studied in preclinical prostate cancer models where it demonstrates 30- to 60-fold greater potency than linomide. Animals are administered Tasquinimod, and samples are analyzed using LC-MS/MS with Tasquinimod-d3 as the internal standard.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tasquinimod-d3 include a molecular weight of 409.4 g/mol and a molecular formula of C20H17F3N2O4. The compound is supplied at ≥98% purity with up to 99.34% isotopic enrichment. Storage recommendations include standard conditions for research compounds. The deuterated isotopologue is validated for plasma, serum, and tissue homogenate quantification. It can be used for deuterium kinetic isotope effect investigations in CYP3A4-mediated metabolic clearance assays.
|
| Toxicity/Toxicokinetics |
Toxicity information for Tasquinimod-d3 is limited, as it is an analytical internal standard rather than a therapeutic agent. The parent compound Tasquinimod has been investigated in clinical studies for safety and tolerability. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References |
|
| Additional Infomation |
Tasquinimod-d3 (ABR-215050-d3) is a deuterium-labeled isotopologue of Tasquinimod, an oral anti-angiogenic agent for castration-resistant prostate cancer. It serves as an internal standard for LC-MS/MS bioanalysis with +3 Da mass shift. Tasquinimod binds HDAC4 Zn²⁺ domain with Kd 10-30 nM. It has MW 409.4 and formula C20H17F3N2O4. It is intended for research use only.
|
| Exact Mass |
409.133
|
|---|---|
| CAS # |
1416701-99-9
|
| PubChem CID |
71487425
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
686
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N(C1=CC=C(C=C1)C(F)(F)F)C(=O)C2=C(C3=C(C=CC=C3OC)N(C2=O)C)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~244.28 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
